Genetic Variants of Complement Factor H Y402H (rs1061170), C2 R102G (rs2230199), and C3 E318D (rs9332739) and Response to Intravitreal Anti-VEGF Treatment in Patients with Exudative Age-Related Macular Degeneration.

: To assess the association between the single nucleotide polymorphisms (SNPs) in the genes encoding complement factors CFH, C2, and C3 (Y402H rs1061170, R102G rs2230199, and E318D rs9332739, respectively) and response to intravitreal anti-vascular endothelial growth factor (VEGF) therapy in patients with exudative age-related macular degeneration (AMD). : The study included 111 patients with exudative AMD treated with intravitreal bevacizumab or ranibizumab injections. Response to therapy was assessed on the basis of best-corrected visual acuity (BCVA) and central retinal thickness (CRT) measured every 4 weeks for 12 months. The control group included 58 individuals without AMD. The SNPs were genotyped by a real-time polymerase chain reaction in genomic DNA isolated from peripheral blood samples. : The CC genotype in SNP rs1061170 of the gene was more frequent in patients with AMD than in controls ( = 0.0058). It was also more common among the 28 patients (25.2%) with poor response to therapy compared with good responders ( = 0.0002). Poor responders, especially those without this genotype, benefited from switching to another anti-VEGF drug. At the last follow-up assessment, carriers of this genotype had significantly worse BCVA ( = 0.0350) and greater CRT ( = 0.0168) than noncarriers. TT genotype carriers showed improved BCVA ( = 0.0467) and reduced CRT compared with CC and CT genotype carriers ( = 0.0194). No associations with AMD or anti-VEGF therapy outcomes for SNP rs9332739 in the gene and SNP rs2230199 in the gene were found. : The CC genotype for SNP rs1061170 in the gene was associated with AMD in our population. Additionally, it promoted a poor response to anti-VEGF therapy. On the other hand, TT genotype carriers showed better functional and anatomical response to anti-VEGF therapy at 12 months than carriers of the other genotypes for this SNP.